Background: Methotrexate (MTX) is the prior drug in ectopic pregnancy (EP).
| INTRODUC TI ON
Ectopic pregnancy (EP) is a common acute abdomen occurring in 1% of all pregnancies, and its incidence is increasing in recent years in China. 1 Patients with EP tend to be younger and have more birth demand. 2 Mostly, patients with EP are identified by hCG levels monitoring and ultrasound scans before they have developed clinical symptoms. 3, 4 Therefore, conservative medication becomes the predominant treatment in EP, which is reasonable and economical practice.
Methotrexate (MTX), as a folate antagonist, is the priority drug of EP, which binds to the catalytic site of dihydrofolate reductase (DHFR) . At a lower intracellular concentration, MTX appears DNA synthesis obstruction by interrupting the synthesis of purine nucleotides, thereby presents an inhibitory effect on gestation trophoblastic. 5 However, effect of MTX is individual difference in EP patients. 5%-30% of patients have a risk of secondary surgery or a supplementary dosage due to failure by first MTX treatment. 6 Several studies had confirmed that genetic factors played an important role in the treatment of acute lymphoblastic leukemia relapse or rheumatoid arthritis with MTX. 7, 8 Nevertheless, the relationship between genetic factors and the efficacy of MTX was rarely reported on the EP therapy.
Methotrexate is a polar molecule and difficult to cross cell membranes. Reduced folate carrier 1 (RFC1) has a high affinity for various hydrophilic antifolates, which is the major influx system for MTX. 9 DHFR coverts folates to their active forms included dihydrofolate (DHF) and tetrahydrofolate (THF), which are essential for purine synthesis. The activity of DHFR was inhibited by intracellular MTX and its active metabolites methotrexate polyglutamates (MTX-PGs). 10 Methylene tetrahydrofolate reductase (MTHFR), a key enzyme of folate metabolism, is the competitive protein of folate, MTX and MTX-PGs. Expression level of DHFR and MTHFR impacts the efficacy of MTX.
Genetic polymorphisms may affect the activity and function of RFC1, MTHFR, and DHFR, and then, influent the uptake and efficacy of MTX. In this study, we focus on the association between clinical efficacy of MTX and genetic polymorphisms including RFC1 G80A, MTHFR C677T, and DHFR A-317G, respectively. 
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| Characteristics of patients
The patient characteristics of EP were described in 
| Association between genetic polymorphisms and successful MTX treatment in ectopic pregnancy
The relationship between the genotypes and treatment success was shown in Table 2 and Table 3 . MTHFR C677T was associated with successful MTX treatment (P = .017). Meanwhile, a higher success rate of first MTX injection in patients with harboring mutation allele of MTHFR gene was observed than that in patients with wild-type gene (P = .001). However, no significant association was found between surgical treatment and polymorphisms of RFC1 and DHFR (P = .709 and 0.476, respectively). In addition, there was also no significant relationship between the polymorphisms of RFC1, DHFR, and success rate in the first MTX injection (P = .661 and .238, respectively). 
| Association between genetic polymorphisms and β-hCG level after MTX treatment in ectopic pregnancy
The relationship between genotypes and β-hCG level changes was showed in Table 4 . There was no correlation between β-hCG levels and genotypes of RFC1, MTHFR, and DHFR before treatment (P = .463, .207, and .458, respectively). β-hCG level at day 4 was significant association with MTHFR C677T (P = .009), whereas the decrement of β-hCG level in 4 days was indifference (P = .197). There were no significant differences on β-hCG level at day 4 (P = .144 and .436, respectively) and day 7 (P = .063 and .943, respectively) among polymorphisms of RFC1 and DHFR.
| D ISCUSS I ON
As a transporter of folacin, RFC1 plays a critical role in membrane transport of MXT and its metabolites. RFC1 participates in regulating cellular uptake of MTX and cellular efflux of MTX-PGs. 12, 13 RFC1
G80A impairs transporting of MTX into cells caused a lower level of MTX. 14 Intercellular MTX is converted to more active MTX-PGs with up to seven glutamyl residues (MTX-PG 1 to MTX-PG 7 ). Longer chain polyglutamates have longer antifolate effects, with better retained in cells. 13 Dervieux et al concluded that there was a higher level of intracellular MTX-PG 5 in patients with RFC1 80AA genotype . 15 In fact, there is correlation between RFC1 G80A and efficacy of MTX in several diseases. A meta-analysis demonstrated that odd of MTX efficacy is increased by 49% for those carrying AA genotype in rheumatoid arthritis patients. 8 Laverdière et al showed that children harboring A allele of RFC1 had a significantly worse prognosis than that harboring G allele in acute lymphoblastic leukemia. 16 The survival was also associated with the genetic polymorphism of RFC1 G80A in osteosarcoma patients treated with MTX. 17 However, our results showed that there was no association with RFC1 G80A on either failure treatment with MTX or β-hCG level decrement after MTX treatment. The absence of correlation maybe due to the lower dosage of MTX for tubal EP therapy, implying that the dosage is a critical factor for genetic polymorphisms of RFC1 in modifying the inhibitory effect of MTX on proliferation of trophocytes.
C677T is one of the most common single nucleotide polymorphism in MTHFR gene. Enzyme activity is reduced by 30% and 65% in genotypes CT and TT carriers, respectively. 18 Patients harboring T allele were almost accompanied by an increased toxicity and decreased efficacy in several studies, while those results are still contradictory. 19 Chen Y et al concluded that C677T polymorphism of MTHFR predicts nonresponse and adverse effects of MTX in juvenile idiopathic arthritis. 20 However, two studies implied that MTHFR C677T was not associated with MXT failure and β-hCG concentration changes during MTX treatment in patients with tubal EP. 21, 22 Interestingly, our results showed that CC carriers had a lower suc- β-hCG level over 5000 mIU/mL before treatment is a crucial factor to indicate failure treatment with MTX. 11 Therefore, those patients were excluded to avoid the interference in the present study.
The dosage of MTX for efficacy on EP is likely to weaken the impact of heredity factors. In addition, some limitations may be ruled out by a number of samples.
In conclusion, our results suggest that MTHFR C677T polymorphism be a reliable indicator of failure treatment with MTX. There is no association among genetic polymorphisms (RFC1 and DHFR), successful MTX treatment, and β-hCG reduction. However, large randomized prospective studies will be needed to effectively replicate and validate these findings.
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